|
DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and 2,300 generic ingredients from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 4,300 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices. |
Generic Name: fosaprepitant dimeglumine
Clinical Trials for: fosaprepitant dimeglumineA Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3) Status: Recruiting Condition: Chemotherapy-Induced Nausea and Vomiting Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children Under 18 Years of Age (MK-0517-029 AM3) Status: Recruiting Condition: Chemotherapy-induced Nausea and Vomiting A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability Status: Completed Condition: Chemotherapy-Induced Nausea and Vomiting Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183)(COMPLETED) Status: Completed Condition: Chemotherapy-Induced Nausea and Vomiting (CINV) Efficacy of Aprepitant (Emend®) in Children Status: Not yet recruiting Condition: Nausea; Vomiting; Childhood Cancer Re-examination Study of EMEND (Aprepitant) (MK-0869-184 AM1) Status: Completed Condition: Chemotherapy-induced Nausea and Vomiting Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting Status: Active, not recruiting Condition: Ovarian Cancer; Uterine Cancer Study of Aprepitant / Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in Colorectal Cancer Patients - SENRI Trial Status: Recruiting Condition: Colorectal Cancer A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208 AM3) Status: Active, not recruiting Condition: Chemotherapy Induced Nausea and Vomiting Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients Status: Completed Condition: Lymphoma Courtesy of ClinicalTrials.org See more clinical trials for this drug | |
Glossary
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist_Flag | Patent Expiration | Patented / Exclusive Use | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Merck And Co Inc | EMEND | fosaprepitant dimeglumine | POWDER; INTRAVENOUS | 022023 | Nov 12, 2010 | RX | Yes | <disabled> | NEW CHEMICAL ENTITY | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Merck And Co Inc | EMEND | fosaprepitant dimeglumine | POWDER; INTRAVENOUS | 022023 | Nov 12, 2010 | RX | Yes | <disabled> | SINGLE IV DOSE OF FOSAPREPITANT 150MG, DOSED CONCOMITANTLY WITH 5HT3 RECEPTOR ANTAGONIST & CORTICOSTEROID, FORPREVENTION OF ACUTE & DELAYED NAUSEA & VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OFHIGHLY EMETOGENIC CANCER CHEMO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Merck And Co Inc | EMEND | fosaprepitant dimeglumine | POWDER; INTRAVENOUS | 022023 | Nov 12, 2010 | RX | Yes | 5,538,982 | <disabled> | PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Merck And Co Inc | EMEND | fosaprepitant dimeglumine | POWDER; INTRAVENOUS | 022023 | Nov 12, 2010 | RX | Yes | 7,214,692 | <disabled> | PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| The preview shows a limited data set. Complete access is available with a Subscription | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
« Back to Dashboard
DrugPatentWatch Archives
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Connect with Social Media:
Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639
`abc